Table 2—

Summary of study findings with pramlintide, exenatide, liraglutide, and vildagliptin

Treatment maximum dosageType of diabetesOther treatmentnDuration (weeks)Baseline A1C (%)Placebo-adjusted ΔA1C (%)Baseline BMI (kg/m2)Placebo-adjusted Δweight (kg)
Whitehouse 2002Pramlintide 60 μg q.i.d.Type 1Insulin480528.7–8.9−0.2725.2–25.8−1.5
Ratner 2004Pramlintide 60 μg q.i.d.Type 1Insulin651528.9−0.3026.3–26.8−1.2
Ratner 2002Pramlintide 150 μg t.i.d.Type 2Insulin538529.2−0.4430.1–30.4−2.5
Hollander 2003Pramlintide 120 μg b.i.d.Type 2Insulin656529.1−0.4034−2.1
DeFronzo 2005Exenatide 10 μg b.i.d.Type 2Metformin272308.2−0.934.2−2.5
Buse 2004Exenatide 10 μg b.i.d.Type 2Sulfonylurea377308.6−0.9833−1.0
Kendall 2005Exenatide 10 μg b.i.d.Type 2Metformin/sulfonylurea733308.5−1.033.6−0.9
Madsbad 2004Liraglutide 0.75 mg onceType 2Diet193127.6−0.7530.3–31.9−0.39
Ahren 2004Vildagliptin 50 mg onceType 2Metformin107127.7–7.9−0.729.4–30.2−0